{"log_id": 29357551744582873, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 6e-06, "average": 0.998601, "min": 0.989251}, "location": {"width": 430, "top": 239, "height": 28, "left": 284}, "words": "呼吸、胸腔和纵膈:咳嗽、嗜酸细胞性肺炎"}, {"probability": {"variance": 0.000433, "average": 0.992871, "min": 0.927124}, "location": {"width": 252, "top": 284, "height": 27, "left": 284}, "words": "神经系统:周围神经病变"}, {"probability": {"variance": 0.007207, "average": 0.974232, "min": 0.629214}, "location": {"width": 742, "top": 329, "height": 30, "left": 283}, "words": "皮肤和皮肤软组织:严重皮肤反应,包括史帝文斯一约翰逊"}, {"probability": {"variance": 0.012147, "average": 0.962788, "min": 0.472055}, "location": {"width": 675, "top": 374, "height": 30, "left": 240}, "words": "( tevens- -Johnson)综合症和水泡大疱样皮疹(累及或不累及粘膜)"}, {"probability": {"variance": 5.2e-05, "average": 0.996457, "min": 0.97571}, "location": {"width": 240, "top": 417, "height": 28, "left": 282}, "words": "胃肠道系统恶心、呕吐"}, {"probability": {"variance": 0, "average": 0.998421, "min": 0.99785}, "location": {"width": 82, "top": 469, "height": 27, "left": 243}, "words": "禁忌"}, {"probability": {"variance": 1.7e-05, "average": 0.998019, "min": 0.981292}, "location": {"width": 429, "top": 513, "height": 30, "left": 284}, "words": "已知对达托霉素有过敏反应的患者禁用本品"}, {"probability": {"variance": 0.000271, "average": 0.989973, "min": 0.957212}, "location": {"width": 126, "top": 558, "height": 28, "left": 242}, "words": "〖注意事项"}, {"probability": {"variance": 1.2e-05, "average": 0.996717, "min": 0.987326}, "location": {"width": 278, "top": 596, "height": 29, "left": 279}, "words": "1、速发过敏反应/超敏反应"}, {"probability": {"variance": 0.000761, "average": 0.99286, "min": 0.839437}, "location": {"width": 743, "top": 639, "height": 33, "left": 280}, "words": "已有报道使用抗菌剂(包括本品)引起可能危及生命的速发过敏反应/超敏"}, {"probability": {"variance": 1.2e-05, "average": 0.998376, "min": 0.983598}, "location": {"width": 590, "top": 682, "height": 34, "left": 234}, "words": "反应。如果本品引起过敏反应,应中止给药并采取对症治疗"}, {"probability": {"variance": 5e-06, "average": 0.997752, "min": 0.992445}, "location": {"width": 243, "top": 729, "height": 27, "left": 277}, "words": "2、肌病和横纹肌溶解症"}, {"probability": {"variance": 0.000647, "average": 0.989771, "min": 0.87058}, "location": {"width": 747, "top": 770, "height": 37, "left": 276}, "words": "肌病,定义为肌痛或肌无力,伴有肌酸磷酸激酶(CPK)值增加超过正常值"}, {"probability": {"variance": 0.004041, "average": 0.982846, "min": 0.611512}, "location": {"width": 788, "top": 817, "height": 33, "left": 234}, "words": "上限(ULN)10倍以上。已有使用本品治疗后发生肌病的报道。有报道使用本品"}, {"probability": {"variance": 4e-06, "average": 0.998604, "min": 0.991491}, "location": {"width": 641, "top": 861, "height": 31, "left": 231}, "words": "治疗的患者出现横纹肌溶解症,部分患者可发生急性肾功能衰竭"}, {"probability": {"variance": 4.9e-05, "average": 0.997201, "min": 0.959379}, "location": {"width": 745, "top": 904, "height": 37, "left": 278}, "words": "对于接受本品治疗的患者,应对其肌痛或肌无力,尤其是肢体远端症状的发"}, {"probability": {"variance": 4e-05, "average": 0.996604, "min": 0.969059}, "location": {"width": 790, "top": 950, "height": 32, "left": 232}, "words": "展进行监测。对于接受本品治疗的患者,应在基线时及其后的每周监测其CPK水"}, {"probability": {"variance": 0.005826, "average": 0.982793, "min": 0.528337}, "location": {"width": 789, "top": 993, "height": 37, "left": 232}, "words": "平,并且对于最近或伴随使用HMG-CoA还原酶抑制剂进行治疗或者使用本品治疗"}, {"probability": {"variance": 8e-06, "average": 0.998078, "min": 0.988451}, "location": {"width": 422, "top": 1039, "height": 32, "left": 233}, "words": "期间CPK升高的患者,应进行更频繁的监测"}, {"probability": {"variance": 3.4e-05, "average": 0.996982, "min": 0.969698}, "location": {"width": 734, "top": 1083, "height": 34, "left": 277}, "words": "对于肾损害的患者,应每周对其肾功能和CPK水平进行更频繁的监测。"}, {"probability": {"variance": 0.007098, "average": 0.97391, "min": 0.585304}, "location": {"width": 745, "top": 1127, "height": 36, "left": 276}, "words": "在I、II期临床试验中,当本品给药次数大于每天1次时,CPK升高的几率增"}, {"probability": {"variance": 0.00017, "average": 0.995002, "min": 0.943706}, "location": {"width": 446, "top": 1174, "height": 28, "left": 231}, "words": "加。因此,本品的给药次数不得超过每天1次"}, {"probability": {"variance": 0.001057, "average": 0.987947, "min": 0.817134}, "location": {"width": 743, "top": 1217, "height": 32, "left": 275}, "words": "如果患者出现了无法解释的肌病体征和症状并且CPK水平升高>000/L("}, {"probability": {"variance": 0.009959, "average": 0.946141, "min": 0.62107}, "location": {"width": 781, "top": 1260, "height": 37, "left": 231}, "words": "5XULN),或者患者出现了明显的CPK水平升高2000UL(≥10XULN)但无症状"}, {"probability": {"variance": 0.000117, "average": 0.996324, "min": 0.939335}, "location": {"width": 793, "top": 1304, "height": 36, "left": 228}, "words": "应中止使用本品。另外,对于正暂时接受本品治疗的患者,应考虑停止使用与横"}, {"probability": {"variance": 0.005207, "average": 0.979477, "min": 0.56637}, "location": {"width": 791, "top": 1350, "height": 35, "left": 229}, "words": "纹肌溶解症相关的药物,例如MG-COA还原酶抑制剂(见药物相互作用项下“HMG"}, {"probability": {"variance": 0.007437, "average": 0.963055, "min": 0.696081}, "location": {"width": 211, "top": 1396, "height": 27, "left": 228}, "words": "CoA还原酶抑制剂”)"}, {"probability": {"variance": 7e-06, "average": 0.997041, "min": 0.991731}, "location": {"width": 201, "top": 1442, "height": 28, "left": 272}, "words": "3、嗜酸细胞性肺炎"}, {"probability": {"variance": 1.2e-05, "average": 0.997626, "min": 0.984079}, "location": {"width": 734, "top": 1485, "height": 36, "left": 272}, "words": "给予本品的患者已报告出现嗜酸细胞性肺炎。在与本品相关的报告病例中"}, {"probability": {"variance": 1.1e-05, "average": 0.998637, "min": 0.981098}, "location": {"width": 794, "top": 1529, "height": 37, "left": 227}, "words": "患者出现发热、伴有低氧性呼吸功能不全的呼吸困难和弥散性肺浸润。一般情况"}], "language": 3}